MCK heads into its July 22 earnings report on a quiet footing — the stock up 7% over the past month to $841, with no meaningful pressure building in the lending market or options.
The positioning picture is notably relaxed for a stock sitting just below a consensus analyst target of $940. Short interest has pulled back sharply from its June peak — down nearly 12% from a month ago — and now represents around 3.5% of the free float, a level too modest to carry much narrative weight. Borrowing costs are effectively symbolic at 0.52%, and availability is extraordinarily loose, with shares available to borrow running at more than 58 times current short interest. Options traders are similarly unbothered: the put/call ratio of 0.58 is almost exactly in line with its 20-day average, with a z-score near zero. There is no hedging premium being paid into this print.
The bull and bear debate centres on what the last few months of analyst revisions reveal. Most of the Street kept positive ratings intact but trimmed targets following the May 7 print — JPMorgan maintained Overweight while lowering to $1,015, Barclays held Overweight at $925 in June after cutting from $1,050, and Citigroup's Buy rating stayed in place at $945. The direction of travel has been cautious recalibration, not abandonment. UBS swam against the tide, raising its target to $1,050 after the May results. The mean target of $940 implies roughly 12% upside from current levels, a gap that has narrowed as the stock has rallied but still gives bulls a credible case. Bears are anchored in the momentum deterioration flagged in the ORTEX score data: the 90-day EPS momentum reading collapsed from around 17 to roughly 3.5 since early June, and the 50/200-day moving average ratio has slid from 98 to 93. The recent note on stronger-than-expected Q1 results and a raised full-year guide complicates that bearish read, but the score degradation suggests the market isn't fully convinced the growth trajectory holds.
One angle worth noting is the pattern of CEO Brian Scott Tyler selling in a near-mechanical cadence — three tranches totalling roughly $17M between early June and early July, each at prices well below the current $841 close. The significance scores on each transaction are low, suggesting pre-scheduled plan sales rather than discretionary positioning. At the same time, CAH — McKesson's closest peer by correlation — fell 3% on the week while MCK gained 4%, a divergence that points to stock-specific buying rather than a sector-wide lift.
Tuesday's print will test whether the raised full-year guidance from May's Q1 release survives contact with a quarter in which specialty pharmacy volumes and oncology drug distribution margins faced incremental policy uncertainty — and whether the narrowing gap between the current price and Wall Street's consensus target can hold.
See the live data behind this article on ORTEX.
Open MCK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
